Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
BioNTech ends Phase 2 trial of autogene cevumeran in colorectal cancerAug 28Clinical readoutautogene cevumeranBioNTech SE